Editas Medicine (EDIT) AI Stock Analysis

• Market Cap: $185.84M
• Dividend Yield: N/A
• Average Volume (3M): 2.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.28
• Revenue Growth: -48.37%
• EPS Growth: -44.70%
• Country: US
• Employees: 246
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.92
• Shares Outstanding: 83,712,860
• 10 Day Avg. Volume: 2,977,057
• 30 Day Avg. Volume: 2,214,246
• PEG Ratio: -0.34
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.36
• Enterprise Value/Market Cap: 2.75
• Enterprise Value/Revenue: 2.60
• Enterprise Value/Gross Profit: 16.27
• Enterprise Value/Ebitda: -0.56
• 1Y Price Target: $3.14
• Price Target Upside: 39.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 60 Neutral
• Price Target: $2.00 ▼(-11.11%Downside)

Editas Medicine's promising advancements in gene editing drive a positive outlook, contributing significantly to its score. However, financial challenges, including lack of revenue and negative cash flow, weigh heavily on the overall assessment. The technical indicators suggest strong market interest, while traditional valuation metrics remain a concern.

Positive Factors

Financial Position

Editas ended 1Q25 with $221M in cash and cash equivalents, expected to provide an operational runway into 2Q27.

Preclinical Data

Editas has shown highly promising preclinical data from their Sickle Cell Disease (SCD) and liver programs, positioning itself as a leader in in vivo editing.

Technology and Efficacy

Editas may achieve best-in-class efficacy in sickle cell disease and beta-thalassemia if successful in replicating reni-cel data.

Negative Factors

Clinical Data Timeline

The long road to initial clinical data remains a key holdup of the stock.

Financial Performance

Editas reported a net loss per share that was larger than the consensus expectations.

Legal Uncertainty

There is increasing uncertainty surrounding the Cas9 patent interference case as it has been remanded back to the PTAB for reconsideration.

Editas Medicine Business Overview & Revenue Model

Company Description

Editas Medicine (EDIT) is a leading biotechnology company focused on developing transformative genomic medicines. The company specializes in the field of gene editing, primarily utilizing CRISPR technology, to develop treatments for a wide range of serious diseases. By applying its proprietary gene-editing platform, Editas aims to create innovative therapies that can potentially correct genetic defects at their source, offering new possibilities for patients with unmet medical needs.

How the Company Makes Money

Editas Medicine generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales of products developed using Editas' technology. Additionally, the company may receive government grants and research funding to support its R&D activities. Although Editas is still in the development stage and does not yet have commercial products, its revenue model is heavily reliant on advancing its drug candidates through clinical trials and securing regulatory approvals to eventually bring its therapies to market.

Editas Medicine Financial Statement Overview

Summary

Editas Medicine faces significant financial challenges typical of biotech firms in the R&D phase. Despite strong cash reserves, the lack of revenue growth and persistent losses indicate difficulties in transitioning to a commercially viable model. Continuous negative cash flow suggests an ongoing reliance on external funding.

Income Statement

Editas Medicine has shown a volatile revenue trajectory with a significant drop to zero revenue in 2024 from previous levels. The company has consistently reported negative net income, leading to negative profit margins. This indicates challenges in achieving profitability, common in the biotech industry, which often requires substantial R&D investments without immediate revenue.

Balance Sheet

The company's balance sheet exhibits moderate financial health with a significant cash reserve relative to its total assets. The debt-to-equity ratio is low, suggesting conservative use of debt. However, the continuous decline in stockholders' equity indicates erosion of shareholder value, which is a concern.

Cash Flow

Editas Medicine has consistently faced negative operating and free cash flows, reflecting operational struggles and high cash burn. Although there are instances of positive financing cash flows, this is likely due to capital raises rather than operational efficiency, posing a risk to long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.84M	32.31M	78.12M	19.71M	25.54M	90.73M
Gross Profit	31.44M	26.50M	-99.53M	13.38M	20.49M	-67.26M
EBITDA	-246.99M	-231.28M	-163.12M	-219.61M	-188.09M	-130.88M
Net Income	-251.23M	-237.09M	-153.22M	-204.35M	-185.11M	-109.41M
Balance Sheet
Total Assets	263.65M	341.59M	499.15M	514.32M	677.48M	572.60M
Cash, Cash Equivalents and Short-Term Investments	220.96M	269.91M	323.11M	437.37M	619.91M	511.77M
Total Debt	31.13M	35.03M	36.54M	43.95M	26.38M	26.14M
Total Liabilities	201.23M	207.31M	150.06M	153.64M	123.84M	179.02M
Stockholders Equity	62.42M	134.27M	349.10M	360.68M	553.64M	393.59M
Cash Flow
Free Cash Flow	-215.28M	-219.11M	-136.90M	-181.47M	-171.78M	-187.00M
Operating Cash Flow	-208.21M	-210.28M	-132.18M	-177.35M	-163.80M	-179.84M
Investing Cash Flow	223.28M	162.15M	-3.73M	114.07M	-54.47M	-140.52M
Financing Cash Flow	54.40M	56.03M	118.04M	1.28M	282.11M	224.12M

Editas Medicine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDIT, the sentiment is Positive. The current price of 2.25 is above the 20-day moving average (MA) of 1.98, above the 50-day MA of 1.68, and above the 200-day MA of 2.05, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 61.58 is Neutral, neither overbought nor oversold. The STOCH value of 44.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EDIT.

Editas Medicine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EDIT	60 Neutral	$185.84M	―	-140.82%	―	-48.37%	-44.70%
Sector *	51 Neutral	$7.36B	0.28	-61.07%	2.37%	17.46%	1.71%
CLLS	48 Neutral	$107.48M	―	-58.55%	―	825.97%	38.32%
NKTX	39 Underperform	$123.82M	―	-26.10%	―	―	30.76%
RAPT	39 Underperform	$122.86M	―	-75.60%	―	―	-2.29%
CTNM	39 Underperform	$106.59M	―	-91.32%	―	-100.00%	-244.85%
NMRA	33 Underperform	$127.09M	―	-79.05%	―	―	-0.42%

Editas Medicine Corporate Events

Editas Medicine Unveils Promising Gene Editing Data

On June 12, 2025, Editas Medicine announced new in vivo data at the European Hematology Association 2025 Congress, demonstrating significant advancements in gene editing for sickle cell disease and beta thalassemia. The study showed that a single dose of their proprietary targeted lipid nanoparticle (tLNP) in non-human primates achieved a 58% mean on-target editing level in the HBG1/2 promoter region of hematopoietic stem cells, surpassing the therapeutic threshold. This development supports the potential of Editas’ approach to provide a novel treatment for these conditions, with favorable biodistribution and minimal liver targeting, enhancing the company’s position in the gene editing industry.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.

Editas Medicine Stockholders Approve Key Amendments

At the 2025 Annual Meeting of Stockholders held on May 29, Editas Medicine, Inc.’s stockholders approved significant amendments to the company’s 2015 Stock Incentive Plan, extending its term and eliminating the ‘evergreen’ provision, among other changes. Additionally, stockholders approved an increase in the number of authorized shares of the company’s capital stock, which could impact the company’s ability to raise capital and expand its operations.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.

Editas Medicine Unveils Promising Gene Editing Data

On May 14, 2025, Editas Medicine announced new in vivo data showcasing the potential of their gene upregulation strategy in hematopoietic stem cells (HSCs) at the American Society of Gene and Cell Therapy Annual Meeting. The data demonstrated that a single dose of their proprietary targeted lipid nanoparticle (tLNP) achieved therapeutically relevant levels of HBG1/2 promoter editing in both humanized mice and non-human primates, exceeding the predicted therapeutic threshold. This approach, which targets HBG1/2 promoters to upregulate fetal hemoglobin, is in pre-clinical development for treating sickle cell disease and beta thalassemia, potentially positioning Editas Medicine as a leader in in vivo gene editing therapies.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.

Editas Medicine Unveils In Vivo Gene Editing Data

On May 13, 2025, Editas Medicine announced in vivo proof of concept data for a liver target at the American Society of Gene and Cell Therapy Annual Meeting. The study demonstrated significant gene editing and protein upregulation in mice and monkeys, indicating potential for a first-in-class treatment for liver diseases. This advancement positions Editas as a leader in gene editing therapies, with plans to reveal more details about the target and development candidate later in the year.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.